| NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease |
803 |
| 2019 Alzheimer's disease facts and figures |
426 |
| Vascular dysfunction-The disregarded partner of Alzheimer's disease |
80 |
| CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts |
73 |
| Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography |
68 |
| Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged >= 65 years |
68 |
| Understanding the impact of sex and gender in Alzheimer's disease: A call to action |
58 |
| The antimicrobial protection hypothesis of Alzheimer's disease |
57 |
| The cost of Alzheimer's disease in China and re-estimation of costs worldwide |
51 |
| Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome |
49 |
| Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals |
47 |
| Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States |
42 |
| Evidence for brain glucose dysregulation in Alzheimer's disease |
42 |
| Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial |
42 |
| Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative |
41 |
| Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need |
41 |
| Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study |
40 |
| Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia |
39 |
| Concordance between the assessment of A beta T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid |
32 |
| Preventing dementia by preventing stroke: The Berlin Manifesto |
32 |
| 2018 Alzheimer's disease facts and figures |
31 |
| Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype |
29 |
| Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease |
29 |
| Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts |
28 |
| Sex, amyloid, and APOE epsilon 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts |
28 |
| Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease |
27 |
| A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment |
27 |
| Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms |
26 |
| Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study |
26 |
| Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging |
26 |
| Inflammatory biomarkers in Alzheimer's disease plasma |
25 |
| Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A beta(1-42), total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40 |
24 |
| Stroke and dementia risk: A systematic review and meta-analysis |
24 |
| Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease |
24 |
| Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies |
23 |
| Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations |
22 |
| The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable |
22 |
| Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study |
22 |
| Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers |
22 |
| Predicting diagnosis and cognition with F-18-AV-1451 tau PET and structural MRI in Alzheimer's disease |
21 |
| Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases |
21 |
| Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota |
21 |
| Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum |
21 |
| Identifying dementia cases with routinely collected health data: A systematic review |
20 |
| Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease |
20 |
| Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology |
20 |
| Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study |
20 |
| Coronary heart disease, heart failure, and the risk of dementia: A systematic review and meta-analysis |
19 |
| Multisite study of the relationships between antemortem [C-11]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology |
19 |
| Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults |
19 |
| Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease |
19 |
| The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies |
19 |
| Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease |
19 |
| Effects of APOE-epsilon 4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease |
19 |
| Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers |
18 |
| A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer's disease |
18 |
| Post-traumatic stress disorder and risk of dementia among members of a health care delivery system |
18 |
| PET staging of amyloidosis using striatum |
18 |
| Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of population-based evidence |
17 |
| Prediabetes and diabetes accelerate cognitive decline and predict microvascular lesions: A population-based cohort study |
17 |
| Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology |
17 |
| Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016 |
16 |
| Inflammatory markers and the risk of dementia and Alzheimer's disease: A meta-analysis |
16 |
| Cortical microstructural changes along the Alzheimer's disease continuum |
15 |
| Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study |
15 |
| Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases |
15 |
| Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting |
15 |
| Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease |
15 |
| Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease |
15 |
| The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials |
15 |
| Sleep disturbances and dementia risk: A multicenter study |
15 |
| Prevalence of the apolipoprotein E epsilon 4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease |
15 |
| A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data |
15 |
| Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content |
14 |
| Clinical outcomes in older surgical patients with mild cognitive impairment |
14 |
| Association of midlife lipids with 20-year cognitive change: A cohort study |
14 |
| A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium |
14 |
| Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease |
14 |
| The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review |
14 |
| Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2 |
13 |
| Plasma apolipoprotein E levels and risk of dementia: A Mendelian randomization study of 562 individuals |
13 |
| Concomitant vascular and neurodegenerative pathologies double the risk of dementia |
13 |
| Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities Study |
13 |
| Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease |
12 |
| Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid |
12 |
| Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease |
12 |
| Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs |
12 |
| Dietary changes and cognition over 2 years within a multidomain intervention trial-The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) |
12 |
| The limbic and neocortical contribution of alpha-synuclein, tau, and amyloid beta to disease duration in dementia with Lewy bodies |
12 |
| Free water determines diffusion alterations and clinical status in cerebral small vessel disease |
12 |
| Detecting agitation and aggression in people with dementia using sensors-A systematic review |
12 |
| Use of nonintrusive sensor-based information and communication technology for real-world evidence for clinical trials in dementia |
12 |
| Physical activity modifies the influence of apolipoprotein E epsilon 4 allele and type 2 diabetes on dementia and cognitive impairment among older Mexican Americans |
12 |
| Cost-effectiveness of a collaborative dementia care management-Results of a cluster-randomized controlled trial |
12 |
| Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome |
12 |
| MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study |
11 |
| Amyloid beta synaptotoxicity is Wnt-PCP dependent and blocked by fasudil |
11 |
| Ethical adoption: A new imperative in the development of technology for dementia |
11 |
| Dental care utilization in patients with different types of dementia: A longitudinal nationwide study of 037 individuals |
11 |
| Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms |
11 |
| Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration |
11 |
| Blood DNA methylation as a potential biomarker of dementia: A systematic review |
11 |
| The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology |
11 |
| The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach |
10 |
| Cerebrospinal fluid alpha-synuclein contributes to the differential diagnosis of Alzheimer's disease |
10 |
| Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies |
10 |
| The Alzheimer's Disease Exposome |
10 |
| Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study |
10 |
| Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study |
10 |
| Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease |
10 |
| Molecular imaging in dementia: Past, present, and future |
10 |
| Cerebrospinal fluid tau, A beta, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration |
10 |
| Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints |
10 |
| A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis |
10 |
| Practical risk score for 5 10 and 20-year prediction of dementia in elderly persons: Framingham Heart Study |
10 |
| Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project |
10 |
| Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale |
10 |
| Association of cerebrospinal fluid alpha-synuclein with total and phospho-tau(181) protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers |
10 |
| AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease |
9 |
| Genetic overlap between vascular pathologies and Alzheimer's dementia and potential causal mechanisms |
9 |
| Profound degeneration of wake-promoting neurons in Alzheimer's disease |
9 |
| N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-beta oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease |
9 |
| Consent recommendations for research and international data sharing involving persons with dementia |
9 |
| Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials |
9 |
| The effects of 7-week cognitive training in patients with vascular cognitive impairment, no dementia (the Cog-VACCINE study): A randomized controlled trial |
9 |
| Failure to detect an association between self-reported traumatic brain injury and Alzheimer's disease neuropathology and dementia |
9 |
| Early versus late MCI: Improved MCI staging using a neuropsychological approach |
9 |
| Motoric cognitive risk syndrome and predictors of transition to dementia: A multicenter study |
9 |
| Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging |
9 |
| The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes |
9 |
| Does traumatic brain injury hold the key to the Alzheimer's disease puzzle? |
9 |
| Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource |
9 |
| Doublecortin expression in CD8+T-cells and microglia at sites of amyloid-beta plaques: A potential role in shaping plaque pathology? |
8 |
| Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials |
8 |
| Prevalence and correlates of mild cognitive impairment among diverse Hispanics/Latinos: Study of Latinos-Investigation of Neurocognitive Aging results |
8 |
| Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging |
8 |
| Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics |
8 |
| Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages |
8 |
| Progress and future challenges in aging and diversity research in the United States |
8 |
| Genetic screen in a large series of patients with primary progressive aphasia |
8 |
| Hypertension and obesity moderate the relationship between beta-amyloid and cognitive decline in midlife |
8 |
| Principles for central nervous system inflammation research: A call for a consortium approach |
8 |
| Predictors of emergency department attendance by people with dementia in their last year of life: Retrospective cohort study using linked clinical and administrative data |
8 |
| Olfactory dysfunction in Alzheimer's disease- and Lewy body-related cognitive impairment |
8 |
| Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort |
8 |
| Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease |
7 |
| Home is where the future is: The BrightFocus Foundation consensus panel on dementia care |
7 |
| CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease |
7 |
| Quantitative gait, cognitive decline, and incident dementia: The Rotterdam Study |
7 |
| European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials |
7 |
| Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition |
7 |
| Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer's disease preceding the disease pathology and cognitive decline |
7 |
| Longitudinal study of hearing loss and subjective cognitive function decline in men |
7 |
| Midlife cardiovascular health and 20-year cognitive decline: Atherosclerosis Risk in Communities Study results |
7 |
| Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation |
7 |
| DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia |
7 |
| Synaptic vesicle cycle and amyloid beta: Biting the hand that feeds |
7 |
| APOE DNA methylation is altered in Lewy body dementia |
7 |
| Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome |
6 |
| Current and past leisure time physical activity in relation to risk of Alzheimer's disease in older adults |
6 |
| Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease |
6 |
| Dementia: Paradigm shifting into high gear |
6 |
| Mechanical stress increases brain amyloid beta, tau, and alpha-synuclein concentrations in wild-type mice |
6 |
| Incidence of dementia in elderly Latin Americans: Results of the Maracaibo Aging Study |
6 |
| What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the US general public |
6 |
| Peripheral complement interactions with amyloid beta peptide in Alzheimer's disease: 2. Relationship to amyloid beta immunotherapy |
6 |
| Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias |
6 |
| GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies |
6 |
| Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative |
6 |
| Retinal signs and risk of incident dementia in the Atherosclerosis Risk in Communities study |
6 |
| Fractal regulation and incident Alzheimer's disease in elderly individuals |
6 |
| Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys |
6 |
| APOE-epsilon 4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies |
6 |
| Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a gray zone? |
6 |
| Added value of F-18-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study |
5 |
| Peripheral complement interactions with amyloid beta peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1 |
5 |
| Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework |
5 |
| Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years |
5 |
| Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease |
5 |
| Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study |
5 |
| Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait? |
5 |
| Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease |
5 |
| Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia |
5 |
| Helicobacter pylori and the risk of dementia: A population-based study |
5 |
| Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial |
5 |
| Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries |
5 |
| Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay |
5 |
| Individualized clinical management of patients at risk for Alzheimer's dementia |
5 |
| Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease |
5 |
| F-18-FDG PET, the early phases and the delivery rate of F-18-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against O-15-H2O PET |
5 |
| Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study |
5 |
| Genetic resilience to Alzheimer's disease in APOE epsilon 4 homozygotes: A systematic review |
5 |
| Sex-specific association between neighborhood characteristics and dementia: The Three-City cohort |
5 |
| The stability of neuropsychiatric subsyndromes in Alzheimer's disease |
5 |
| Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia |
5 |
| Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging |
5 |
| Military-related risk factors for dementia |
4 |
| Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort |
4 |
| The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease |
4 |
| Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status |
4 |
